CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
March 2018—Genoptix and Rosetta Genomics announced they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a total gross purchase price of $10 million. The transaction is expected to close during the first quarter of 2018, subject to approval by Rosetta Genomics’ shareholders and customary closing conditions. Upon closing, Rosetta Genomics will become a wholly owned subsidiary of Genoptix.
Genoptix, 760-268-6200